Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
How has the primary ciliary dyskinesia (pcd) market size changed in recent years, and what is the outlook ahead?
The primary ciliary dyskinesia market size has grown strongly in recent years. It will grow from $0.46 billion in 2024 to $0.50 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increasing clinical confusion with other respiratory disorders, expanded reliance on symptomatic treatment, enhanced use of general respiratory therapies, expanded diagnosis based on exclusion methods, and increasing focus on cystic fibrosis overshadowing primary ciliary dyskinesia.
The primary ciliary dyskinesia market size is expected to see strong growth in the next few years. It will grow to $0.65 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to growing awareness of rare respiratory diseases, improved genetic testing availability, rising cases of chronic respiratory infections, better reimbursement policies, and expansion of specialized diagnostic centers. Major trends in the forecast period include advancement in genetic sequencing technologies, development of non-invasive diagnostic tools, increasing research and development collaborations, innovations in airway clearance devices, and integration of artificial intelligence in diagnostic imaging.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24386&type=smp
What are the top economic and technological drivers pushing primary ciliary dyskinesia (pcd) market growth?
The rising demand for gene therapy is expected to propel the growth of the primary ciliary dyskinesia market going forward. Gene therapy is a treatment that modifies or replaces faulty genes in a patient’s cells to cure or prevent diseases. The demand for gene therapy is growing due to progress in genetic research, enabling more accurate treatments that target and correct genetic disorders at the molecular level, enhancing patient outcomes. Researchers are developing gene therapy for Primary Ciliary Dyskinesia (PCD) to correct the genetic mutations that cause faulty cilia function in the respiratory system. This therapy introduces healthy genes to restore normal ciliary movement, improve mucus clearance, and reduce respiratory infections. For instance, in July 2023, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, in the first quarter of 2023, there were 247 gene therapy programs in Phase II clinical trials, and this number increased by 5%, reaching a total of 260 ongoing Phase II gene therapy trials by the end of the second quarter. Therefore, the rising demand for gene therapy is driving the growth of the primary ciliary dyskinesia market.
How is the primary ciliary dyskinesia (pcd) market segmented by product, application, and end-user?
The primary ciliary dyskinesia (PCD) market covered in this report is segmented –
1) By Treatment: Antibiotics, Airway Clearance Therapies, Surgical Interventions, Other Treatments
2) By Method: Genetic Testing, Imaging Techniques, Clinical Evaluation, Lung Function Tests
4) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Retail Pharmacies
4) By End-User: Hospitals, Specialty Clinics, Diagnostic Laboratories, Other End-Users
Subsegments:
1) By Antibiotics: Macrolides, Penicillins, Cephalosporins, Fluoroquinolones, Aminoglycosides
2) By Airway Clearance Therapies: Chest Physiotherapy, High-Frequency Chest Wall Oscillation (HFCWO), Positive Expiratory Pressure (PEP) Therapy, Intrapulmonary Percussive Ventilation (IPV), Oscillatory Positive Expiratory Pressure (OPEP)
3) By Surgical Interventions: Sinus Surgery, Tympanostomy Tube Placement, Lung Transplantation
4) By Other Treatments: Mucolytics, Immunomodulatory Therapies, Gene Therapy, Stem Cell Therapy
View The Full Market Report:
What technological trends are expected to redefine the primary ciliary dyskinesia (pcd) market?
Major companies operating in the primary ciliary dyskinesia market are focusing on developing innovative solutions, such as investigational mRNA-based therapeutics, to improve symptom management and enhance patients’ quality of life. An investigational mRNA-based therapeutic is a developing treatment that utilizes messenger RNA (mRNA) to direct cells to produce proteins that may treat or prevent diseases. This cutting-edge method targets conditions at the molecular level, paving the way for personalized medicine. For instance, in June 2024, ReCode Therapeutics, Inc., a US-based biotechnology company, launched RCT1100, an investigational inhaled mRNA therapy. It received approval from the Food and Drug Administration (FDA) for orphan drug designation to treat primary ciliary dyskinesia. RCT1100 aims to restore ciliary function by delivering DNAI1 mRNA directly to airway cells, addressing a critical unmet need for the estimated 45,000 affected individuals in the U.S., as there are currently no disease-modifying treatments or cures for PCD.
Which leading companies are dominating the primary ciliary dyskinesia (pcd) market landscape?
Major companies operating in the primary ciliary dyskinesia (PCD) market are Centogene N.V., Nationwide Children’s Hospital, Revvity Inc., Quest Diagnostics Incorporated, Children’s Healthcare of Atlanta, Exact Sciences Corp., University Hospital Southampton, UT Health East Texas, Guy’s and St Thomas’ NHS Foundation Trust, National Jewish Health, Vanderbilt University Medical Center, UNC School of Medicine, Stanford Medicine, Mayo Foundation for Medical Education and Research, DNA Labs India Pvt. Ltd., Parion Sciences Inc., ReCode Therapeutics Inc., University Hospital Münster, UAB Health System, PCD Foundatio
Which geographic areas are expected to offer the highest growth opportunities in theprimary ciliary dyskinesia (pcd) market?
North America was the largest region in the primary ciliary dyskinesia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary ciliary dyskinesia (PCD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Primary Ciliary Dyskinesia (PCD) Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24386&type=smp
Need Customized Data On Primary Ciliary Dyskinesia (PCD) Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24386&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
